Unveiling the myQA Blue Phantom³ for Quality Assurance
IBA (Ion Beam Applications S.A.), a global frontrunner in particle accelerator technology, has launched the myQA Blue Phantom³ at the prestigious European Society for Radiotherapy and Oncology (ESTRO) congress. This advanced solution promises to reshape radiotherapy quality assurance by improving both precision and efficiency in treatment delivery.
Revolutionary Features of myQA Blue Phantom³
The myQA Blue Phantom³ system stands out with its ability to achieve automatic levelling in less than 30 seconds, making it the fastest offering currently available in the market. This capability is particularly vital during the commissioning process, where time efficiency is crucial. With integrated real-time, contactless positioning control, medical physicists can enjoy certified measurement precision, ensuring the accuracy of results thanks to its embedded reference class electrometer.
Commitment to Safety and Quality in Radiation Therapy
IBA remains dedicated to enhancing the quality and precision of radiation therapy delivery, which in turn significantly boosts patient safety. With a legacy of over half a century in the dosimetry market, IBA has established itself as the trusted validation partner of choice for leading linear accelerator manufacturers. This strong partnership allows clinicians access to innovative tools that enable them to provide accurate and effective treatments.
Expert Insights from Leadership
Commenting on the launch, Jean-Marc Bothy, President of IBA Dosimetry, expressed pride in unveiling this advanced water phantom product after 50 years since the introduction of the first digital water phantom on the market. He emphasized IBA’s commitment to innovation, stating that they continuously strive to incorporate the latest advancements in radiation therapy and imaging into their offerings, ensuring users can treat more patients safely and efficiently.
About IBA: A Leader in Particle Accelerator Technology
IBA, headquartered in Louvain-la-Neuve, Belgium, is recognized as the premier supplier of equipment and services in proton therapy, considered the most advanced form of radiation therapy today. The company also excels in industrial sterilization, radiopharmaceuticals, and dosimetry. With a workforce of around 2,100 people globally, IBA is a certified B Corporation, meeting rigorous standards for social and environmental performance.
Stock Information
IBA is publicly traded on the pan-European stock exchange EURONEXT, listed under the ticker IBAB. This highlights the company's significant stature within the industry and its commitment to transparency and shareholder engagement.
Frequently Asked Questions
What is the myQA Blue Phantom³ used for?
The myQA Blue Phantom³ is utilized for quality assurance in radiotherapy, ensuring precision and efficiency in treatment delivery.
How fast does myQA Blue Phantom³ level?
This innovative system achieves automatic levelling in under 30 seconds, the quickest available on the market.
Who is IBA's target audience?
IBA primarily targets medical professionals such as medical physicists and radiotherapy clinicians who require advanced quality assurance tools.
What does IBA do?
IBA specializes in providing cutting-edge technology and services in proton therapy, industrial sterilization, radiopharmaceuticals, and dosimetry.
How many employees does IBA have?
IBA employs approximately 2,100 professionals across the globe, reflecting its strong presence in the healthcare technology sector.
